Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MTX-531 + Trametinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MTX-531 | MTX531|MTX 531 | EGFR Inhibitor (Pan) 62 PI3K Inhibitor (Pan) 42 | MTX-531 inhibits EGFR and PI3K, which results in decreased Egfr and Pi3k signaling and potentially leads to increased apoptosis and decreased tumor growth (PMID: 38992135). | |
Trametinib | Mekinist | GSK1120212 | MEK inhibitor (Pan) 26 MEK1 Inhibitor 26 MEK2 Inhibitor 24 | Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafenib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E, and for pediatric patients of 1 year or older with low-grade glioma harboring BRAF V600E (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | sensitive | MTX-531 + Trametinib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of Mekinist (trametinib) and MTX-531 inhibited tumor growth with a 40% partial response rate and increased survival in a patient-derived xenograft (PDX) model of colorectal cancer harboring BRAF V600E (PMID: 38992135). | 38992135 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|